Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients

Idir Ouzaid, Solène Florence Kammerer-Jacquet, Zineddine Khene, Alain Ravaud, Jean-Jacques Patard, Karim Bensalah, Nathalie Rioux-Leclercq, Idir Ouzaid, Solène Florence Kammerer-Jacquet, Zineddine Khene, Alain Ravaud, Jean-Jacques Patard, Karim Bensalah, Nathalie Rioux-Leclercq

Abstract

Objective: We aimed to explore biological predictive factors of progression after surgery in nonmetastatic renal cell carcinoma (RCC) using the collected tumors in the French cohort of the randomized S-TRAC trial patients. Patients and Methods: We analyzed the tumors of the French cohort of STRAC that included 44 cases of clear cell RCC (ccRCC) that were collected from six centers. The main objective was to explore biological predictive factors of progression (defined as PFS) to sunitinib. Broad-spectrum analysis including immunohistochemistry, fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH) array, and transcriptomic analyses were performed on the tumors. Results:Analysis of vascular density showed type 1 vascular stroma corresponding to high vascular density was associated with progression (p < 0.034). Loss of poly bromo-1 expression showed a distinct profile: a highly histopathological aggressive tumor with a marked angiogenic profile (vascular endothelial growth factor overexpression and immature vascular stroma type 2), no PD1 or PDL1 expression, and wild-type (WT) status of the VHL gene. There were 27 chromosome regions gained in patients with progression (on chromosomes 7 and 16, and to a lesser extent 8, 12, 17, 17, 19, 20 corresponding to 605 associated genes) and 10 regions lost in these same patients on chromosomes 8 and 9, and to a lesser extent 2 and 21 corresponding to 25 associated genes. Conclusion:We found that an angiogenic phenotype defined by a high vascular density with a vascular type 2 stroma was a predictive factor of sunitinib resistance. Regardless of adjuvant treatment, chromosomal gains and losses and genomic alterations including PBRM1 loss were associated with worse outcomes. Clinical Trial Registration: ClinicalTrials.gov number, NCT00375674.

Keywords: angiogenesis; prognosis; progression; renal cell carcinoma; sunitinib; vascular endothelial growth factor.

Copyright © 2020 Ouzaid, Kammerer-Jacquet, Khene, Ravaud, Patard, Bensalah and Rioux-Leclercq.

Figures

Figure 1
Figure 1
(A) Type 2 (low density). (B) Type 1 (high density) vascular stoma.
Figure 2
Figure 2
Findings on CGH arrays according to progression status during the follow-up after radical nephrectomy.

References

    1. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. (2015) 67:519–30. 10.1016/j.eururo.2014.10.002
    1. Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, et al. . Updated European Association of urology guidelines regarding adjuvant therapy for renal cell carcinoma. Eur Urol. (2017) 71:719–22. 10.1016/j.eururo.2016.11.034
    1. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. (2005) 174:466–72. 10.1097/01.ju.0000165572.38887.da
    1. Cersosimo RJ. Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 1. Am J Health Syst Pharm. (2009) 66:1525–36. 10.2146/ajhp080387.p1
    1. Cersosimo RJ. Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2. Am J Health Syst Pharm. (2009) 66:1625–33. 10.2146/ajhp080387.p2
    1. Bandini M, Smith A, Marchioni M, Pompe RS, Martel TF, Cindolo L, et al. . Adjuvant therapies in nonmetastatic renal-cell carcinoma: a review of the literature. Clin Genitourin Cancer. (2018) 16:176–83. 10.1016/j.clgc.2018.01.003
    1. Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. (2017) 35:3916–23. 10.1200/JCO.2017.73.5324
    1. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. (2016) 387:2008–16. 10.1016/S0140-6736(16)00559-6
    1. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. . Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. (2016) 375:2246–54. 10.1056/NEJMoa1611406
    1. Patard J-J, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. . Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. (2004) 22:3316–22. 10.1200/JCO.2004.09.104
    1. Rioux-Leclercq N, Epstein JI, Bansard JY, Turlin B, Patard JJ, Manunta A, et al. . Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol. (2001) 32:1209–15. 10.1053/hupa.2001.28957
    1. Dagher J, Kammerer-Jacquet S-F, Brunot A, Pladys A, Patard J-J, Bensalah K, et al. . Wild-type VHL clear cell renal cell carcinomas are a distinct clinical and histologic entity: a 10-year follow-up. Eur Urol Focus. (2016) 1:284–90. 10.1016/j.euf.2015.06.001
    1. Massari F, Di Nunno V, Mollica V, Graham J, Gatto L, Heng D. Adjuvant tyrosine kinase inhibitors in treatment of renal cell carcinoma: a meta-analysis of available clinical trials. Clin Genitourin Cancer. (2019) 17:e339–44. 10.1016/j.clgc.2018.12.011
    1. Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, et al. . Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell. (2018) 173:581–94.e12. 10.1016/j.cell.2018.03.057
    1. Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, et al. . Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell. (2018) 173:595–610.e11. 10.1016/j.cell.2018.03.043
    1. Cancer Genome Atlas Research Network . Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. (2013) 499:43–9. 10.1038/nature12222
    1. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. . Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. (2011) 469:539–42. 10.1038/nature09639
    1. da Costa WH, Rezende M, Carneiro FC, Rocha RM, da Cunha IW, Carraro DM, et al. . Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma. BJU Int. (2014) 113:E157–63. 10.1111/bju.12426
    1. Pawłowski R, Mühl SM, Sulser T, Krek W, Moch H, Schraml P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer. (2013) 132:E11–7. 10.1002/ijc.27822
    1. Qian C-N, Huang D, Wondergem B, Teh BT. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer. (2009) 115:2282–9. 10.1002/cncr.24238
    1. Yao X, Qian C-N, Zhang Z-F, Tan M-H, Kort EJ, Yang XJ, et al. . Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res. (2007) 13:161–9. 10.1158/1078-0432.CCR-06-0774
    1. Rojas JD, Papadopoulou V, Czernuszewicz TJ, Rajamahendiran RM, Chytil A, Chiang Y-C, et al. . Ultrasound measurement of vascular density to evaluate response to anti-angiogenic therapy in renal cell carcinoma. IEEE Trans Biomed Eng. (2019) 66:873–80. 10.1109/TBME.2018.2860932
    1. George DJ, Martini J-F, Staehler M, Motzer RJ, Magheli A, Donskov F, et al. . Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory pharmacogenomic analysis. Clin Cancer Res. (2019) 25:1165–73. 10.1158/1078-0432.CCR-18-1724
    1. Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, et al. . A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. (2015) 16:676–85. 10.1016/S1470-2045(15)70167-1
    1. Rini BI, Escudier B, Martini J-F, Magheli A, Svedman C, Lopatin M, et al. . Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase III trial of adjuvant sunitinib. Clin Cancer Res. (2018) 24:4407–15. 10.1158/1078-0432.CCR-18-0323
    1. Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Lond Engl. (2019) 393:2404–15. 10.1016/S0140-6736(19)30723-8
    1. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. . Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. (2019) 380:1116–27. 10.1056/NEJMoa1816714
    1. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. . Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. (2019) 380:1103–15. 10.1056/NEJMoa1816047
    1. Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, et al. . Updated European Association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. (2019) 76:151–6. 10.1016/j.eururo.2019.05.022
    1. Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, et al. . Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res. (2015) 21:1329–39. 10.1158/1078-0432.CCR-14-1128
    1. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. (2018) 24:749–57. 10.1038/s41591-018-0053-3

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する